Skip to content

Van lent Pharma

Active Private limited companyfounded 2021active for 5 yearsKarel Van Doorslaerlaan 68, 2880 BornemKBO/BCE: BE 0774.450.473

Lifetime

4 annual accounts with figures on one time axis
peak of €107,430 in 2025
€107,430▲ 13×
peak of €80,052 in 2025
€80,052▲ 17×
peak of €93,264 in 2024
€82,552▼ 11.5%
€13,733▲ 45.8%
Board1 name since 2021
1 director
Documentsfilings and deeds
15-07-202616 days before the deadline
2025micro format
Gross margin from €8,446 to €107,430Result from €4,745 to €80,052Dividend €90,764Debts from €9,418 to €13,733

Key points

from the 2025 annual accounts

Equity

€82,552 ▼ 11.5%
93,2642024+80,052Profit-90,764Dividend82,5522025

Van lent Pharma paid out €90,764 in dividends. That is 113% of the 2025 profit.

Result

€80,052 ▲ 17×
€4,7402024€80,1002025

The result rose in 2025 from €4,745 to €80,052.

Turnover

≈ €160,000 estimated

The micro format states no turnover.

Liquidity

7.27 was 10.74 in 2024

Short-term debts rose from €9,418 to €13,094.

Filings

4 annual accounts since 2022
AprilJune31 JulyOctober2022202320242025

The last four annual accounts were filed 16 to 53 days before the end of the period.

Position in the sector

€80,052

Higher net result than 86% of companies in office administrative support. The sector median is €15,226, over 10,284 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 26,977 companies had the same profile as Van lent Pharma has now. Each dot stands for 68 companies, two years later.

94.9%
were still trading
3.5%
stopped another way
1.6%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 26,977 companies, not a prediction for Van lent Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 24-09-2021
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0774450473
Registered office moved to Bornem The registered office moved from Kapelstraat 78 bus 1.21 to Karel Van Doorslaerlaan 68 te 2880 Bornem · General meeting of 26-10-2022 · Gazette deed
First establishment Karel Van Doorslaerlaan 68, Bornem
Incorporation Founding capital of €2,500, 100 shares · Founded by · appointed as director · published on 24-09-2021 · Gazette deed
All 11 events

Comparable companies

same main activity, similar in size and age
Company
Van lent Pharma Bornem €96,286 €107,430 85.7% -
CRO Consulting Zandhoven €98,559 €102,757 2.5% -
K& Concepts Westerlo €109,241 €106,819 72.8% -
ABLOC Zandhoven €102,241 €100,907 76.1% -
Structic Malle €92,255 €97,290 10.4% -
Borre Heist-op-den-Berg €118,965 €124,492 9.6% -
Arvipro Herent €105,442 €105,195 10.7% -

These companies have the same main activity as Van lent Pharma: other business support services (NACE 82990). They are comparable in size and age: total assets between €92,300 and €119,000, founded between 2021 and 2022.

Official details

Source: KBO
Status
Active since 22-09-2021Normal situation
Activity
Other business support servicesNACE 82990
Establishment unit
2.322.076.1692880 Bornem, since 01-10-2021
Financial year end
31 December
Peppol
Reachable since 22-10-2025
Company details

Annual accounts 2025

€96,286▼ 6.2%
Filing
Filed on 15-07-2026, 16 days before the end of the filing period
Financials

Insights on Van lent Pharma

Van lent Pharma files the micro format. That format states no turnover. The gross margin rose from €54,891 in 2022 to €107,430 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Van lent Pharma

What is the company number of Van lent Pharma?
The company number of Van lent Pharma is 0774.450.473. The VAT number is the same number with BE in front: BE 0774.450.473.
Where is Van lent Pharma based?
The registered office is at Karel Van Doorslaerlaan 68, 2880 Bornem.Company details
What does Van lent Pharma do?
According to the KBO register, the main activity is other business support services (NACE 82990).
What is the legal form of Van lent Pharma?
Van lent Pharma is a private limited company (BV).
When was Van lent Pharma founded?
Van lent Pharma was founded on 22-09-2021.
Is Van lent Pharma still active?
Yes, Van lent Pharma is an active enterprise in the KBO register.
What is the turnover of Van lent Pharma?
The turnover in financial year 2025 is about €160,000. This figure is estimated from the gross margin of €107,430 and 31 comparable companies (NACE 82990). It probably lies between €130,000 and €220,000.Financials
Is Van lent Pharma profitable?
In financial year 2025, Van lent Pharma made a profit of €80,052.
Where can I find the annual accounts of Van lent Pharma?
Van lent Pharma filed 4 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Van lent Pharma due?
Van lent Pharma must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.